Assenagon Asset Management S.A. 13F: Adds $477M to HUM Stake

Assenagon Asset Management S.A. made a massive addition to its health insurance holdings, according to a Form 13F filing with the SEC on October 15, 2026. The institutional investor reported a dramatic increase in its position in Humana Inc. (NYSE: HUM), jumping heavily into the stock during the reported period. Because 13F filings look backward at holdings from the previous quarter, this update shows where the fund stood at that time and may not reflect its exact portfolio today.

What Changed in Assenagon Asset Management S.A.'s Humana Inc. Position

The fund added 1,249,272 shares to its holdings, representing a staggering 20,126.8% increase over its previous count of just 6,207 shares. Assenagon finished the period holding 1,255,479 shares of Humana, with a reported total value of $479,053,122.

Other Institutional Activity in Humana Inc.

Other large institutional investors also made notable adjustments to their Humana holdings around the same time. Dodge & Cox Inc. reduced its holdings by 440,438 shares, ending with 10,940,380 shares worth about $4,520,127,440. Blackrock Inc. grew its holdings by 218,270 shares, ending with 10,417,803 shares worth about $4,304,219,525. Vanguard Capital Management LLC grew its holdings by 4,703 shares, ending with 7,843,620 shares worth about $3,240,670,067. Vanguard Portfolio Management LLC grew its holdings by 10,455 shares, ending with 5,818,956 shares worth about $2,404,159,882. State Street Corporation grew its holdings by 3,817 shares, ending with 5,457,072 shares worth about $2,254,643,887.

Humana Inc. Stock Down 1.9%

Humana shares recently traded around $419.41 as of October 16, 2026. That price puts the stock up about 39.7% above its 200-day moving average and sitting below its 52-week high of $456.50. Analysts currently have a consensus buy rating on the stock with a mean price target of $465.12.

Recent Earnings

For its trailing-twelve-month period, Humana reported revenue of $145,679,007,744 and earnings of $10.88 per share. The company posted a net margin of 0.9% and a return on equity of 6.9%. The health insurer's next quarterly earnings report is scheduled for release on November 6, 2026.

Dividend

Humana pays an annual dividend with a yield of 0.82% and a payout ratio of 33.5%.

Insider Buying and Selling at Humana Inc.

Officer Sanjay K Shetty bought 810 shares of stock on February 23, 2026, at an average price of $185.20 for a total value of $150,016.

Analysts Set New Price Targets

On October 12, 2026, UBS maintained its Neutral rating on the stock while raising its price target to $495.00 from $405.00. On the same day, Truist Securities maintained its Hold rating and raised its target to $475.00 from $415.00. Oppenheimer maintained an Outperform rating on October 12, lifting its target from $475.00 to $525.00. Raymond James upgraded the stock to Outperform on October 12 with a $520.00 price target. Mizuho followed on October 13 by maintaining an Outperform rating and raising its target to $495.00 from $468.00. Overall, the company carries a buy consensus across 24 analyst opinions.

About Humana Inc.

Humana Inc. provides medical and specialty insurance products to customers across the United States. It operates primarily through its Insurance and CenterWell segments, delivering health care services and coverage plans. Major institutional investments like Assenagon's highlight how large asset managers position themselves within the healthcare sector ahead of upcoming earnings reports.

Bottom Line

Investors should keep an eye on Humana's upcoming earnings report on November 6, 2026, for fresh details on financial performance and member enrollment trends. Regulatory filings like Assenagon's 13F offer a helpful look at institutional interest, though they reflect past positions rather than live trading activity. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.